Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
NCT06065046Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in traumatic brain injury (TBI), sponsored by Tangdu Hospital. Started Nov 2023; status: recruiting.
02
Drugs
baricitinib
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT06065046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065046.